{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:21:13Z","timestamp":1779376873484,"version":"3.53.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"am","delay-in-days":286,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.anndiagpath.2022.151913","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T11:44:17Z","timestamp":1644493457000},"page":"151913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies"],"prefix":"10.1016","volume":"58","author":[{"given":"Sugeshnee","family":"Pather","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moosa","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2022.151913_bb0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.26333","article-title":"A million Africans a year dying from cancer by 2030: what can cancer research and control offer to the continent?","volume":"130","author":"Sylla","year":"2012","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.anndiagpath.2022.151913_bb0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1470-2045(08)70175-X","article-title":"Part I: cancer in indigenous Africans\u2013burden, distribution, and trends","volume":"9","author":"Parkin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0015","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"291","article-title":"Diffuse large B-cell lymphoma, NOS","author":"Gascoyne","year":"2017"},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4236\/jct.2015.66057","article-title":"The impact of human immunodeficiency virus infection (HIV) on lymphoma in South Africa","volume":"6","author":"Patel","year":"2015","journal-title":"J Cancer Ther"},{"issue":"8","key":"10.1016\/j.anndiagpath.2022.151913_bb0030","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.anndiagpath.2022.151913_bb0035","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151913_bb0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2559.2008.03076.x","article-title":"MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type","volume":"53","author":"Yoon","year":"2008","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151913_bb0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3324\/haematol.2009.012864","article-title":"Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma","volume":"95","author":"Stasik","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151913_bb0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2141.2011.08675.x","article-title":"Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"155","author":"Testoni","year":"2011","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2022.151913_bb0055","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1309\/AJCP2Z0TAGMUYJEB","article-title":"Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma","volume":"139","author":"Valentino","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151913_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033813","article-title":"Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas","volume":"7","author":"Kluk","year":"2012","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.anndiagpath.2022.151913_bb0065","doi-asserted-by":"crossref","first-page":"18374","DOI":"10.18632\/oncotarget.4073","article-title":"MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151913_bb0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0075","series-title":"Diffuse large B-cell lymphoma in adults at Chirs Hani Baragwanath Academic Hospital, Master of Medicine research report","author":"Machailo","year":"2016"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151913_bb0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.pathol.2020.02.007","article-title":"Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: an analysis by cell-of-origin, Epstein-Barr virus infection and survival","volume":"52","author":"Cassim","year":"2020","journal-title":"Pathology"},{"issue":"23","key":"10.1016\/j.anndiagpath.2022.151913_bb0085","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0090","series-title":"The fifth South African national HIV prevalence, incidence, behaviour and communication survey, 2017: HIV impact assessment summary report","year":"2018"},{"issue":"5","key":"10.1016\/j.anndiagpath.2022.151913_bb0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1473-3099(06)70463-7","article-title":"Immunological recovery and antiretroviral therapy in HIV-1 infection","volume":"6","author":"Battegay","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"9513","key":"10.1016\/j.anndiagpath.2022.151913_bb0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":"Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anndiagpath.2022.151913_bb0105","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1086\/597093","article-title":"Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment","volume":"48","author":"Kelley","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151913_bb0110","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s00268-020-05899-z","article-title":"Compromised gut associated lymphoid tissue is a risk factor for postoperative septic complications in HIV-seropositive trauma patients","volume":"45","author":"Mauser","year":"2021","journal-title":"World J Surg"},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-011110-130254","article-title":"Pathogenic mechanisms of HIV disease","volume":"6","author":"Moir","year":"2011","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151913_bb0120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/599313","article-title":"Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma","volume":"200","author":"Zoufaly","year":"2009","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.anndiagpath.2022.151913_bb0125","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I treat HIV-associated lymphoma","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.anndiagpath.2022.151913_bb0130","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.anndiagpath.2022.151913_bb0135","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0140","doi-asserted-by":"crossref","DOI":"10.21037\/aol.2018.12.02","article-title":"Aggressive B-cell lymphomas-from morphology to molecular pathogenesis","volume":"3","author":"Chen","year":"2019","journal-title":"Ann Lymphoma"},{"issue":"12","key":"10.1016\/j.anndiagpath.2022.151913_bb0145","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/jjco\/hyu155","article-title":"Clinical characteristics and treatment outcome in a Taiwanese population of patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"44","author":"Lu","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"273","key":"10.1016\/j.anndiagpath.2022.151913_bb0150","article-title":"The impact of HIV on non-Hodgkin's lymphoma at Chris Hani Baragwanath Hospital","volume":"92","author":"Patel","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.anndiagpath.2022.151913_bb0155","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.anndiagpath.2022.151913_bb0160","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.anndiagpath.2022.151913_bb0165","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2005-09-3600","article-title":"AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy","volume":"107","author":"Mounier","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.anndiagpath.2022.151913_bb0170","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s12253-013-9632-2","article-title":"Large cell lymphoma: correlation of HIV status and prognosis with differentiation profiles assessed by immunophenotyping","volume":"19","author":"Pather","year":"2013","journal-title":"Pathol Oncol Res"},{"issue":"30","key":"10.1016\/j.anndiagpath.2022.151913_bb0175","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","article-title":"Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034","volume":"27","author":"Chadburn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151913_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/MCB.19.1.1","article-title":"c-Myc target genes involved in cell growth, apoptosis and metabolism","volume":"19","author":"Dang","year":"1999","journal-title":"Mol Cell Biol."},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0185","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014217","article-title":"MYC, metabolism, cell growth and tumorigenesis","volume":"3","author":"Dang","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"10.1016\/j.anndiagpath.2022.151913_bb0190","first-page":"5914","article-title":"An amino-terminal c-Myc domain required for neoplastic transformation activates transcription","volume":"10","author":"Kato","year":"1990","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2022.151913_bb0195","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/j.1460-2075.1991.tb07929.x","article-title":"The MYC protein activates transcription of the alpha-prothymosin gene","volume":"10","author":"Eilers","year":"1991","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.anndiagpath.2022.151913_bb0200","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccr.2005.08.005","article-title":"The great MYC escape in tumorigenesis","volume":"8","author":"Dang","year":"2005","journal-title":"Cancer Cell"},{"issue":"7052","key":"10.1016\/j.anndiagpath.2022.151913_bb0205","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature03845","article-title":"Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants","volume":"436","author":"Hemann","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.anndiagpath.2022.151913_bb0210","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.anndiagpath.2022.151913_bb0215","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/PAS.0000000000000433","article-title":"MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC\/BCL2 protein double-positive diffuse large B-cell lymphoma","volume":"39","author":"Wang","year":"2015","journal-title":"American Journal of Surgical Pathology"},{"key":"10.1016\/j.anndiagpath.2022.151913_bb0220","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.anndiagpath.2022.151913_bb0225","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)","volume":"136","author":"Ramos","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.anndiagpath.2022.151913_bb0230","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-14-2083","article-title":"A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection","volume":"21","author":"Chao","year":"2015","journal-title":"Clinical cancer research\u202f: an official journal of the American Association for Cancer Research"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913422000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:34:55Z","timestamp":1761078895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913422000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":45,"alternative-id":["S1092913422000156"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151913","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2022.151913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151913"}}